J Bone Metab.  2020 Feb;27(1):15-26. 10.11005/jbm.2020.27.1.15.

Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review

• Shin YH
• Shin WC
• Kim JW

• KMID: 2471310
• DOI: http://doi.org/10.11005/jbm.2020.27.1.15

Abstract

A systematic search was conducted and relevant studies that evaluated the influence of osteoporosis medications (bisphosphonates [BPs], denosumab, selective estrogen receptor modulators [SERMs], recombinant human parathyroid hormone teriparatide [TPTD], and strontium ranelate [SrR]) on wrist, hip, and spine fracture healing, were selected. BPs administration did not influence fracture healing and clinical outcomes after distal radius fracture (DRF). Similar results were observed in hip fracture, but evidence is lacking for spine fracture. Denosumab did not delay the non-vertebral fractures healing in one well-designed study. No studies evaluated the effect of SERMs on fracture healing in humans. One study reported shorter fracture healing times in TPTD treated DRF patients, which was not clinically meaningful. In hip fracture, recent studies reported better pain and functional outcomes in TPTD treated patients. However, in spine fracture, recent studies found no significant differences in fracture stability between TPTD treated patients and controls. Evidence is lacking for SrR, but it did not influence wrist fracture healing in one study. In comparisons between TPTD and BPs, fracture healing and physical scores were not significantly different in hip fracture by 1 study. In spine fracture, controversy exists for the role of each medication to the fracture stability, but several studies reported that fracture site pain was better in TPTD treated patients than BPs treated patients. Considering no clinical data of negative fracture healing of the antiresorptive medication and the danger of subsequent fracture after initial osteoporotic fracture, there is no evidence to delay initiation of osteoporosis medications after fracture.

Keyword

Denosumab; Diphosphonates; Osteopososis; Osteoporotic fractures; Teriparatide

MeSH Terms

Denosumab
Diphosphonates
Fracture Healing*
Hip
Humans
Osteoporosis*
Osteoporotic Fractures
Parathyroid Hormone
Radius Fractures
Selective Estrogen Receptor Modulators
Spine
Strontium
Teriparatide
Wrist
Denosumab
Diphosphonates
Parathyroid Hormone
Selective Estrogen Receptor Modulators
Strontium
Teriparatide

Reference

1. Khosla S, Cauley JA, Compston J, et al. Addressing the crisis in the treatment of osteoporosis: A path forward. J Bone Miner Res. 2017; 32:424–430. PMID: 28099754.

2. Nakayama A, Major G, Holliday E, et al. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27:873–879. PMID: 26650377.

3. Sietsema DL, Araujo AB, Wang L, et al. The effectiveness of a private orthopaedic practice-based osteoporosis management service to reduce the risk of subsequent fractures. J Bone Joint Surg Am. 2018; 100:1819–1828. PMID: 30399076.

4. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 149:404–415. PMID: 18794560.

5. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49:2–19. PMID: 21555003.

6. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294–1301. PMID: 15598694.

7. Hegde V, Jo JE, Andreopoulou P, et al. Effect of osteoporosis medications on fracture healing. Osteoporos Int. 2016; 27:861–871. PMID: 26419471.

8. Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007; 22:867–876. PMID: 17371160.

9. McDonald MM, Dulai S, Godfrey C, et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008; 43:653–662. PMID: 18582604.

10. van der Poest Clement E, Patka P, Vandormael K, et al. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000; 15:586–593. PMID: 10750574.

11. Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am. 2009; 34:595–602. PMID: 19345861.

12. Shoji KE, Earp BE, Rozental TD. The effect of bisphosphonates on the clinical and radiographic outcomes of distal radius fractures in women. J Hand Surg Am. 2018; 43:115–122. PMID: 29054355.

13. Gong HS, Song CH, Lee YH, et al. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am. 2012; 94:1729–1736. PMID: 22992762.

14. Uchiyama S, Itsubo T, Nakamura K, et al. Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J. 2013; 95-B:1544–1550. PMID: 24151277.

15. Duckworth AD, McQueen MM, Tuck CE, et al. Effect of alendronic acid on fracture healing: A multicenter randomized placebo-controlled trial. J Bone Miner Res. 2019; 34:1025–1032. PMID: 30845365.

16. Altintaş F, Ozkut AT, Beyzadeoğlu T, et al. The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc. 2007; 41:132–135. PMID: 17483649.

17. Cecilia D, Jódar E, Fernandez C, et al. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int. 2009; 20:903–910. PMID: 18956132.

18. Colón-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011; 22:2329–2336. PMID: 21153021.

19. Kim TY, Ha YC, Kang BJ, et al. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br. 2012; 94:956–960. PMID: 22733953.

20. Lim EJ, Kim JT, Kim CH, et al. Effect of preoperative bisphosphonate treatment on fracture healing after internal fixation treatment of intertrochanteric femoral fractures. Hip Pelvis. 2019; 31:75–81. PMID: 31198773.

21. Ha KY, Park KS, Kim SI, et al. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing? Osteoporos Int. 2016; 27:483–488. PMID: 26202489.

22. Goldhahn J, Feron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012; 90:343–353. PMID: 22451221.

23. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009; 24:196–208. PMID: 19016594.

24. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012; 94:2113–2119. PMID: 23097066.

25. Sahiner T, Aktan E, Kaleli B, et al. The effects of postmenopausal hormone replacement therapy on sympathetic skin response. Maturitas. 1998; 30:85–88. PMID: 9819788.

26. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002; 30:368–376. PMID: 11856644.

27. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002; 17:2237–2246. PMID: 12469918.

28. Beil FT, Barvencik F, Gebauer M, et al. Effects of estrogen on fracture healing in mice. J Trauma. 2010; 69:1259–1265. PMID: 20173660.

29. Spiro AS, Khadem S, Jeschke A, et al. The SERM raloxifene improves diaphyseal fracture healing in mice. J Bone Miner Metab. 2013; 31:629–636. PMID: 23546819.

30. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21:115–137. PMID: 10782361.

31. Friedl G, Turner RT, Evans GL, et al. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res. 2007; 25:1454–1464. PMID: 17557320.

32. Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res. 2007; 22:1903–1912. PMID: 17680724.

33. Nakazawa T, Nakajima A, Shiomi K, et al. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone. 2005; 37:711–719. PMID: 16143574.

34. Manabe T, Mori S, Mashiba T, et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007; 40:1475–1482. PMID: 17369013.

35. Jørgensen NR, Schwarz P. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep. 2011; 9:149–155. PMID: 21698357.

36. Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010; 81:234–236. PMID: 20367417.

37. Shin YH, Gong HS. Recent update in the diagnosis and treatment of bone frailty in patients with a distal radius fracture. J Hand Surg Asian Pac Vol. 2016; 21:307–312. PMID: 27595946.

38. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:404–414. PMID: 19594305.

39. Bhandari M, Jin L, See K, et al. Does teriparatide improve femoral neck fracture healing: Results from a randomized placebo-controlled trial. Clin Orthop Relat Res. 2016; 474:1234–1244. PMID: 26932738.

40. Huang TW, Chuang PY, Lin SJ, et al. Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. Medicine (Baltimore). 2016; 95:e3626. PMID: 27175673.

41. Kim SJ, Park HS, Lee DW, et al. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury. 2019; 50:1364–1370. PMID: 31182230.

42. Tsuchie H, Miyakoshi N, Kasukawa Y, et al. The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab. 2016; 34:86–91. PMID: 25773046.

43. Kitaguchi K, Kashii M, Ebina K, et al. Effects of weekly teriparatide administration for vertebral stability and bony union in patients with acute osteoporotic vertebral fractures. Asian Spine J. 2019; 13:763–771. PMID: 31000686.

44. Min HK, Ahn JH, Ha KY, et al. Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study. Osteoporos Int. 2019; 30:2249–2256. PMID: 31420700.

45. Sibai T, Morgan EF, Einhorn TA. Anabolic agents and bone quality. Clin Orthop Relat Res. 2011; 469:2215–2224. PMID: 21132409.

46. Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013; 38:E487–E492. PMID: 23354115.

47. Ozturan KE, Demir B, Yucel I, et al. Effect of strontium ranelate on fracture healing in the osteoporotic rats. J Orthop Res. 2011; 29:138–142. PMID: 20726035.

48. Li YF, Luo E, Feng G, et al. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariec tomized rats. Osteoporos Int. 2010; 21:1889–1897. PMID: 19957162.

49. Tarantino U, Celi M, Saturnino L, et al. Strontium ranelate and bone healing: report of two cases. Clin Cases Miner Bone Metab. 2010; 7:65–68. PMID: 22461295.

50. Alegre DN, Ribeiro C, Sousa C, et al. Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int. 2012; 32:439–443. PMID: 21120486.

51. Scaglione M, Fabbri L, Casella F, et al. Strontium ranelate as an adjuvant for fracture healing: clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures. Osteoporos Int. 2016; 27:211–218. PMID: 26294293.

52. Aspenberg P, Malouf J, Tarantino U, et al. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: Results of a randomized, active-controlled, double-blind clinical trial at 26 weeks. J Bone Joint Surg Am. 2016; 98:1868–1878. PMID: 27852903.

53. Iwata A, Kanayama M, Oha F, et al. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. BMC Musculoskelet Disord. 2017; 18:148. PMID: 28388910.

54. Kang JH, Yang SM, Im SB, et al. Can three months of teriparatide be one of treatment options for osteoporotic vertebral compression fracture patients? Korean J Neurotrauma. 2019; 15:19–27. PMID: 31098345.

55. Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012; 23:2141–2150. PMID: 22159672.